| pubmed-article:21713076 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0042769 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C1708485 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0205087 | lld:lifeskim |
| pubmed-article:21713076 | lifeskim:mentions | umls-concept:C0457343 | lld:lifeskim |
| pubmed-article:21713076 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21713076 | pubmed:dateCreated | 2011-6-29 | lld:pubmed |
| pubmed-article:21713076 | pubmed:abstractText | Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21713076 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21713076 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:21713076 | pubmed:issn | 2035-3006 | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:LatagliataRob... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:BrecciaMassim... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:AlimenaGiulia... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:GirmeniaCorra... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:SantopietroMi... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:FedericoVince... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:LoglisciGiuse... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:SalaroliAdria... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:SerraoAlessan... | lld:pubmed |
| pubmed-article:21713076 | pubmed:author | pubmed-author:PetrucciLuigi... | lld:pubmed |
| pubmed-article:21713076 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21713076 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:21713076 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21713076 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21713076 | pubmed:pagination | e2011021 | lld:pubmed |
| pubmed-article:21713076 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:21713076 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21713076 | pubmed:articleTitle | Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. | lld:pubmed |
| pubmed-article:21713076 | pubmed:affiliation | Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. | lld:pubmed |
| pubmed-article:21713076 | pubmed:publicationType | Journal Article | lld:pubmed |
